Analyst Research Roundup: Castlight Health, Inc. (CSLT), U.S. Bancorp (USB)

Castlight Health, Inc. (NYSE:CSLT) tinted gains of +0.25% (+0.01 points) to US$3.97. The volume of 0.72 Million shares climbed down over an trading activity of 536.3 Million shares. EPS ratio determined by looking at last 12 month figures is -0.29. Over the same time span, the stock marked US$5.95 as its best level and the lowest price reached was US$1.86. The corporation has a market cap of US$580.69 Million.

Castlight Health, Inc. (NYSE:CSLT)’s earnings per share has been growing at a 16.7 percent rate over the past 5 year when average revenue increase was noted as 64.5 percent. The return on equity ratio or ROE stands at -20.2 percent while most common profitability ratio return on investment (ROI) was -20.1 percent. The company’s institutional ownership is monitored at 72.7 percent. The company’s net profit margin has achieved the current level of -25.4 percent and possesses 61.5 percent gross margin.

Daily Analyst Recommendations

A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 2 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 5 think it is Hold. Recently, analysts have updated the overall rating to 2.33. 2 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.

U.S. Bancorp (NYSE:USB) is worth US$83.41 Billion and has recently risen 0.25% to US$51.71. The latest exchange of 3.56 Million shares is below its average trading activity of 7.42 Million shares. The day began at US$51.73 but the price moved to US$51.49 at one point during the trading and finally capitulating to a session high of US$52.07. The stock tapped a 52-week high of US$55.56 while the mean 12-month price target for the shares is US$55.09.

Currently, the stock carries a price to earnings ratio of 12.48, a price to book ratio of 1.85, and a price to sales ratio of 5.16. For the past 5 years, the company’s revenue has grown 5.7%, while the company’s earnings per share has grown 6.6%. With an institutional ownership near 77.3%, it carries an earnings per share ratio of 4.14.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 3 brokerage firms polled by Factset Research. At present, 15 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 3 analysts call it Underweight, while 4 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 2.72.